Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.89 | N/A | +34.47% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-2.89 | N/A | +34.47% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed caution regarding current market conditions. They did not provide specific guidance for future quarters.
Management highlighted ongoing challenges in the market.
They emphasized the need for strategic adjustments moving forward.
Grail Inc's earnings report shows a larger-than-expected loss per share, which contributed to a significant drop in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's future performance. The stock's 9.2% decline reflects market uncertainty following the announcement.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
EXPEDITORS INTL WASH Class A
Feb 18, 2025